Bull, Bear & Beyond – Medigene: executive interview

Medigene (FSE: MDG1) is a publicly listed, Germany-based, immuno-oncology platform company focused on the development of T cell receptor (TCR)-guided therapies with the aim of effectively eliminating cancer. Medigene has a broad and active pipeline focused on a range of modalities. Notably, lead programme MDG1015 is a first-in-class, third-generation T cell receptor-engineered T cell (TCR-T) therapy, for which, the company recently received US FDA clearance for its investigational new drug application for multiple solid tumour indications. MDG1015 is expected to enter the clinic by end-2024, subject to additional financing.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.